I wasn’t able to listen this. Owning but focusing energy around NASH is the smartest move. Dumping covid a very good move although they should have dumped it after the cd12 underwhelming results. It comes down to NASH being our moonshot folks and I’m all for it. This is the risks CEOs take but without the cash we need for multiple trials , let alone one, this is the best avenue